Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HIV-1 reverse transcriptase ribonuclease H domain is a specialized enzyme domain located at the C-terminus of the p66 subunit in the HIV-1 reverse transcriptase heterodimer. The enzyme has two critical, spatially separated activities: DNA polymerase (which copies viral RNA into DNA) and RNase H (which degrades the RNA strand of RNA/DNA hybrids during reverse transcription)[1][3][4]. The RNase H domain is essential for proper processing and removal of RNA primers, ensuring successful synthesis and integration of the viral DNA into the host genome[1][4]. RNase H function is required for HIV infectivity, making it an established and validated antiviral drug target. While the majority of HIV therapies target the RT polymerase, RNase H remains of interest for novel inhibitor development and overcoming drug resistance[1][2][4].
Inhibition of RNA cleavage in RNA/DNA hybrids, thus blocking conversion of viral RNA into DNA and interfering with viral replication. Blockade of reverse transcription, which prevents HIV-1 from integrating into host DNA[1][2].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 reverse transcriptase ribonuclease H domain (HIV-1 RT RNase H).